Recent Approach to Alzheimer’s Syndrome and Dementia- A Review

Manju Tembhre*

*M K Ponda College, Barkatullah University, Bhopal, India

*Corresponding Author: Manju Tembhre, M K Ponda College, Barkatullah University, Bhopal, India.

Received: August 04, 2017; Published: September 21, 2017

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disease causes depletion in memory, judgment, communication and cognitive functioning. Over the past decades AD is one of the commonly fatal diseases in the baby boomer population. The search for a treatment to Alzheimer’s hasn’t been going well. There are only a few approved drugs that treat symptoms of the disease these are Razadyne (galantamine), Exelon (rivastigmine), Memantine and Aricept (donepezil). In rapid aging of society, neurodegenerative diseases such as Alzheimer’s disease, is widely-recognized as serious problems that need to be addressed. The objective of the present review is to provide the reader with an updated account of Alzheimer’s Syndrome and Dementia and currently available biomarkers for AD and clinically relevant differential diagnoses.

Keywords: Alzheimer’s Disease; Dementia; Biomarkers for AD

Introduction

Alzheimer’s disease (AD) is a slowly progressive, age-related neurodegenerative brain disease and is the most frequent cause of the dementia syndrome in elderly. It was first identified by Alois Alzheimer in 1906 in Germany. It has become a global health concern as the population of ageing people, is growing alarmingly. It is estimated that in 2050, over 80 million people will suffer from AD worldwide and will be a major public health problem [1]. According to the recent report of Alzheimer’s Association [2] the occurrence in 2017 among persons over age 65 is expected to be 5.3 million i.e. one in 10 people or 10 percent have Alzheimer’s dementia in U.S. alone. Autopsy study of dementia victims in Florida found AD pathology in 77% of cases, whereas 26% had Lewy Body Disease, 18% had vascular dementia, 13% had hippocampal sclerosis, and 5% had Fronto Temporal Dementia (FTD) [3].

AD is an irreversible brain disease that slowly destroys memory and thinking skills and eventually even the ability to perform the simplest daily tasks. The main symptoms include memory loss, cognitive impairment, disorientation and psychiatric symptoms [4]. AD pathology begins even much before the arrival of clinical symptoms. Findings of the Dominantly Inherited Alzheimer’s Network (DIAN) study found brain changes starting 10 to 20 years before the commencement of dementia symptoms in people genetically intended to get Alzheimer’s disease [5].

Mapping Alzheimer’s disease involves mainly seven stages [6]. First stage is the earliest phase of normal outward behavior with no apparent symptoms except a PET scan, an imaging can reveal whether the person has got Alzheimer’s. Stage 2 - 4 show very mild, mild and moderate decline changes which include forgetting a word or misplacing objects, forgets something he just read, asks the same question repeatedly, face more trouble making plans or organizing and can’t remember names of new people they meet and the problems in thinking and reasoning such as forget particulars about himself, forget what date, month or season it is and having trouble cooking meals. In the stage 5 moderately severe decline changes showing state of confusion and patient start to lose track of place and time. He develops trouble remembering general information’s like his address and phone number. Stage 6 is severe decline stage with clear symptoms of confusion relating people correctly or delusions such as thinking he needs to go to work even though he has retired long back. The stage 7 is very severe decline phase, a final stage of Alzheimer’s dementia in which secondary symptoms of AD e.g. depression, agitation, aggression, hallucinations, delusions,
sleep disorders appears. The life expectancy of AD patients may vary from 4 - 10 years depending on young or old age. Amalgamation of several causes has made a challenge to investigate pre-dementia diagnosis of AD. It is highly prudent to discover reliable biomarkers, to spot its exact pathophysiology during pre-symptomatic stage. Biomarker(s) with high sensitivity and specificity would facilitate AD diagnosis at early stages. Currently, CSF amyloid β 1-42, total tau, and phosphorylated tau181 are used as AD biomarkers [7].

Despite the increase in aging population affected with AD and its distressing way, and the huge social and economic costs, current treatments are only symptomatic and marginally effective. Recent research in AD focuses mainly on the synthesis drugs that can reverse or slow the advancement of AD and target to beta-amyloid production, aggregation, and clearance, as well as tau phosphorylation and assembly. But up till now none of these drugs have exhibited promising results in III phase of clinical trial [8]. Toward the discovery of such agents, the multi-pronged of mechanisms of its onset must be understood and to formulate appropriate therapies for effective prevention or treatment.

Key Factors of AD: There may be several factors of onset of AD depending on the person’s physiological setup.

**CSF Beta Amyloid (Aβ):** The major cause leading to AD appears to be the formation of a peptide (protein) known as amyloid beta (beta amyloid, Aβ) which clusters into amyloid plaques (senile plaques) on the blood vessels and on the outside surface of neurons of the brain (amyloidosis), which ultimately leads to the killing of neurons. The major constituents of amyloid plaques, are the β-amyloid peptides consisting of 40 and 42 amino acids (Aβ1-40 and Aβ1-42), which are derived from the amyloid precursor protein (APP) present in different cell membranes [9]. There are two enzymes alpha-secretase (α-secretase) and beta-secretase (β-secretase or BACE1 - with the identification of the gene that produces it, beta-secretase has been renamed BACE (Beta-site APP-Cleaving Enzyme) that initially compete to cut APP. If alpha-secretase cuts APP there is no formation of Aβ. If APP is cleaved by beta-secretase it can then be further cleaved by gamma-secretase (γ-secretase) to form either a 40 amino acid amyloid peptide (Aβ40) which is soluble and mostly harmless - or a 42 amino acid peptide (Aβ42) which clusters together to form insoluble amyloid plaques [10]. Beta peptide (Aβ42) is more hydrophobic and “sticky” (and hence aggregates more readily) than the (Aβ40). Alpha-secretase cleavage takes place at the cell surface, whereas beta-secretase acts at the endoplasmic reticulum. Gamma-secretase produces Aβ42 if cleavage occurs in the endoplasmic reticulum, however Aβ40 is formed if the cleavage is in the trans-Golgi network [11]. The β-amyloids become folded in the β-folded or β-pleated shape, and then pile on each other to form long fibrils and aggregates known as plaques in AD patients [12]. The combination of decreased concentrations of Aβ1-42 (or Aβ1-42/Aβ1-40 ratio) and increased concentrations of total tau and P-tau in cerebrospinal fluid (CSF) are also considered to be indicator of stages of Alzheimer’s disease [13]. Treatment strategies include inhibitors of β- and γ-secretase, to prevent aggregation of the amyloids [14]. A number of immune strategies and a cholesterol-decreasing approach are also being assessed to get rid of the β-amyloids.

**CSF Tau Protein:** Alzheimer’s is characterized by massive loss of neurons and disrupted signaling between cells in the brain. One of the important causes of dementia is the involvement of Tau proteins, which aggregate together to form neuronal tangles in the brain of AD patient. In healthy person the Tau protein is connected to microtubules of cytoskeleton of the nerve cell and supports the cell structure. In AD patients’ tau is displaced from the cytoskeleton in the nerve cells and eventually tangles collectively to form protein accumulations that interrupt the nerve cell’s functioning. Actually tau proteins become hyper-phosphorylated and lose the capacity to bind to microtubules. Instead, the phosphorylated tau proteins bind to each other, tying themselves in “knots” (paired helical filaments - two threads of tau wound around each other) known as NeuroFibrillary Tangles (NFTs). Neurons full of NFTs rather than functional microtubules soon die. These NeuroFibrillary Tangles (NFT’s) are made up of paired helical filaments consisting of hyperphosphorylated tau protein (P-tau). Tau protein itself is an intracellular protein that is released upon neuronal death. As clumps or tangles advances the risk of patient’s death rises. If tau is prevented from locking onto the vesicles in the nerve cells in AD patient’s brain, will prevent inhibition of synaptic transmission and also the death of nerve cells [15]. This protein may offer an opportunity for therapeutic intervention. Studies are ongoing with agents that may prevent or reverse excess tau phosphorylation and thereby diminish formation of neurofibrillary tangles.
Cholinesterase Inhibition: Over last five decades it was commonly accepted that Alzheimer's disease (AD) is a lack of the acetylcholine (ACh) in the brain and it has been demonstrated that the inconsistent shortage of neurotransmitter acetylcholine leads to Alzheimer's disease [16]. It is well established that acetylcholinesterase and acetylcholinesterase accountable for acetylcholine synthesis and its degradation are declined in the neocortex and hippocampus areas of the brain involved in cognition and memory [17]. Further, density of nicotinic acetylcholine receptors in the cerebral cortex decreases in AD patients. Muscarinic Acetylcholine receptors play an important role in learning & memory. Over three-quarters of cholinergic neurons in the basal forebrain nuclei are seen to be destroyed in a typical AD autopsy. Loss of choline acetyltransferase in the nucleus basalis was the first biomarker of AD. Centrally acting ChE inhibitors (ChEI) prevent the breakdown of acetylcholine. At present few such agents have been approved by the FDA for the treatment of AD, which are Donepezil, Rivastigmine and Galantamine. Rivastigmine and galantamine inhibit butyrylcholinesterase as well as AChE. Galantamine has a direct stimulant action upon nicotinic receptors. Nausea, vomiting and diarrhea are the most common side effects of the AChE inhibitors. Approximately 50% of AD patients treated with AChE inhibitor show lack of cognitive deterioration for up to two years [18].

Genetic Factors: Tau-protein encoding gene is located on chromosome 17 and is considered not responsible for any Familial AD (FAD). It is the PS1 (Pre-Senilin 1) gene located on chromosome 14 accounts more for FAD. PS1 is the main enzyme cleaving the gamma-secretase site. PS1 is present within the endoplasmic reticulum/Golgi complex. Abnormal proteins from the PS1 and PS2 genes apparently influence gamma-secretase enzyme causing more Aβ42 peptide formation [19]. Numerous lines of evidence suggest that one of the best known genetic key risk factor for Alzheimer's disease in men or women is a gene that carries instructions for a protein called apolipoprotein E (APOE) which transport cholesterol and beta-amyloid in and out of cells. The mutations on chromosome 19 to the APOE gene are described as a “risk factor” for Sporadic AD. APOE gene occurs in three common forms (alleles): APOE2, APOE3 and APOE4. Each person has two copies of chromosome 19, therefore there are 6 combinations of the 3 alleles when taken 2 at a time (e2/e2, e2/e3, e2/e4, e3/e3, e3/e4 and e4/e4). The APOE4 allele increases amyloid deposition on blood vessel walls, the APOE2 allele increases the likelihood of a lobar intra-cerebral hemorrhage [19]. A new study by researchers at the Stanford University School of Medicine reveals that carrying just one copy of the ApoE4 gene results in a two to four times greater risk of Alzheimer’s disease on women than it does on men. Inheriting two copies increases the risk nearly 10 - 15 times [20]. It is still to confirm that why AD is much more prevalent in women than in men for any given age group, but some evidence suggests that it may be due to an interface between the APOE-e4 genotype and the sex hormone estrogen [21]. Studies have shown that estrogen replacement treatment in post-menopausal women can increase cerebral blood flow and improve cognitive performance. On the other hand the brains of men bear the capacity to alter testosterone to estrogen with advancing age, which may explain the greater prevalence of AD among women [22]. The greater longevity also contributes for women’s increased susceptibility to Alzheimer’s. Some studies have suggested that lower educational attainment in women than in men could be a possible reason for a higher risk of Alzheimer’s and other dementias in women [23]. The TOMMORROW trial is enrolling people with a genetically-based increased risk of AD determined through the use of a pharmacogenetic algorithm based on TOMM40 and APOE genotype and age [24]. In Down’s syndrome victims the mutation on chromosome 21 (the chromosome that is present in triplicate in Down’s syndrome) is on the Amyloid Precursor Protein (APP) gene itself, resulting in abnormal APP protein that is preferentially cleaved by secretases to form more Aβ42. Hence Down’s syndrome patients may develop AD by the age of 40 [19].

Biomarkers of AD: Early diagnosis of AD is difficult because early symptoms of the disease are common in a variety of disorders, which reflects general neuropathological features. Conventional diagnosis of AD was based on combination of clinical criteria which includes a neurological examination, mental status tests and brain imaging [25]. But these tests prove to be difficult especially in patients having mild or early stages of AD. There is immense necessity of specific, easy-to-use and responsive biomarkers to distinguish AD from other types of dementia, such as mild cognitive impairment (MCI), or mixed forms of dementia, such as fronto temporal lobe dementia (FTLD), vascular dementia (VaD) or Lewy body dementia (LBD). This is imperative because therapy for these diseases may be different [26,27].

Currently, dementia is diagnosed by analyzing Cerebrospinal Fluid (CSF) with valid biomarkers like β-amyloid (1-42) [Aβ(1-42)], total tau protein and phospho-tau 181expression levels. Decreased CSF concentration of the amyloid- β (1-42) peptide (Aβ) and an increased
level of the protein tau are found in patients with AD [28]. These biomarkers considerably enhance the validity for diagnosis by giving > 95% sensitive and > 85% specific results [29,30]. It has been demonstrated that Amyloid beta is an efficient, highly sensitive and specific biomarker from CSF for AD. Recent researches have shown that Semi-quantitative amyloid PET appears more powerful than CSF markers for AD grading and MCI prognosis in terms of cognitive decline and AD conversion [31].

The analysis of other 199, -231, -235, -396 and -404 forms of phosphorylated tau in CSF might offer indication to early diagnosis of AD [32]. Phospho-tau-231 and phospho-tau-181 are more specific to differentiate AD from controls and FTLD, LBD, VaD and major depression [33]. Increased levels of P-tau have been reported with AD patients compared with patients having FTD and VAD, DLB and Parkinson disease with dementia. P-tau shows 92 and 64% difference with specificities between patients with AD and patients with FTD and DLB respectively [34].

According to findings of Alexopoulos et al. [35] on MCI patients with positive Aβ42 values are at the same risk for AD dementia whether or not they have one positive Tau marker (either t-Tau or p-Tau). Hence, patients with positive Aβ42 and non-positive or conflicting p-Tau/t-Tau levels, is not who cannot be categorized according to the current NIA-AA (National Institute on Aging/Alzheimer’s Association) algorithm, appears under the same dementia risk, which occurs between that of the lowest and highest risk groups.

Recent Research on AD: New studies are focusing on evaluating Aβ as a potential biomarker from blood serum as well. This might help recognize the disease earlier because of the simple method and high frequency of blood collection [36]. Obtaining blood samples is relatively painless and inexpensive, giving potential blood-based biomarkers further advantage over the CSF-based markers. More importantly, efforts are warranted to mine newer biomarkers to prevent AD and dementia and are to search such diagnostic strategy which could be utilized as a prescreening tool to predict cerebral Aβ deposition or other factors lead to AD.

Recent evidence suggests the progressive loss of brain cells seen in Alzheimer’s disease (AD) may be due to brain cells taking up and releasing specific aggregated proteins (misfolded proteins, which clump together). Recently Scientists have reported that the suppression of expression of synapse-restricting protein Ephexin5 restores Alzheimer’s-like impairment in mice [37].

Scientists' have identified a new gene PTPRD (Protein Tyrosine Phosphatase, Receptor type D) gene that is associated with Tau accumulation in the brain. This accumulation occurs in Alzheimer’s disease and certain forms of dementia [38].

Recently a gene called USP9 (Ubiquitin Specific Peptidase 9) is identified that is much more active in the brains of healthy women than in men with AD. This gene has an indirect influence on the tau protein, which is found in higher levels in the AD brain. In addition, they noticed that blocking the USP9 gene significantly reduced the tau activity [39].

AXON Neuroscience, a global leading Biotech Company in development of tau immunotherapies has found promising results from its Phase I trial for the vaccine AADvac1. AADvac1 is an active immunotherapy directed against tau protein, the main constituent of neurofibrillary tangles. Further researches are going on to find safe, correct and targeted therapy of AD.

Conclusion

There is soaring need to discover a potentially new way to get Alzheimer’s medications, a long-standing challenge that could help clear the brain of the build-up of the toxic protein known as amyloid beta (AB) and other factors that leads to Alzheimer’s. Still AD treatment awaits breakthrough, which may take a lot of time for a potential treatment for Alzheimer’s disease to work its way from the laboratory, through rigorous testing and, finally, to become approved by the U.S. Food and Drug Administration (FDA).

Bibliography


Citation: Manju Tembhide. “Recent Approach to Alzheimer’s Syndrome and Dementia- A Review”. EC Pharmacology and Toxicology 4.5 (2017): 165-171.
Recent Approach to Alzheimer’s Syndrome and Dementia- A Review


Citation: Manju Tembhere. “Recent Approach to Alzheimer’s Syndrome and Dementia- A Review”. *EC Pharmacology and Toxicology* 4.5 (2017): 165-171.


*Volume 4 Issue 5 September 2017
© All rights reserved by Manju Tembhre.*